Research map: Efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with extremely high lipoprotein(a) levels >180 mg/dL

Back to the article

Papers in this map

  1. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk · François Mach · 2019 · 9168 citations · Cited by this paper
  2. Assessment of municipal infrastructure related to population lifestyle in the Pskov region · 2026 · Related
  3. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol · Kausik Kumar Ray · 2020 · 1658 citations · Cited by this paper
  4. II International Congress "Therapy and Preventive Medicine". Collection of abstracts · 2026 · Related
  5. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement · Florian Kronenberg · 2022 · 1455 citations · Cited by this paper
  6. Effectiveness of a neural network-based fatal event prediction using conventional risk factors based on thirty-year prospective follow-up · 2026 · Related
  7. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk · Michelle L. O’Donoghue · 2019 · 1001 citations · Cited by this paper
  8. Chronic coronary artery disease as a cause of death: analysis of medical certificates of cause of death from several regions of the Russian Federation · 2026 · Related
  9. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults · Glen J. Pearson · 2021 · 863 citations · Cited by this paper
  10. Impact of blood electrolyte parameters on the incidence of paroxysmal atrial fibrillation in patients with chronic kidney disease with and without albuminuria · 2026 · Related
  11. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome · Vera Bittner · 2020 · 603 citations · Cited by this paper
  12. Cardiac-renal-hepatic-metabolic disease in chronic heart failure (CARMEN-CHF): rationale and design of an observational multicenter prospective study · 2026 · Related
  13. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice · Marlys L. Koschinsky · 2024 · 324 citations · Cited by this paper
  14. Optimization of the diagnosis of cardiovascular adverse events in patients with non-Hodgkin lymphomas · 2026 · Related
  15. Disorders of lipid metabolism. Clinical Guidelines 2023 · Ежов Марат Владиславович · 2023 · 212 citations · Cited by this paper
  16. Structural and functional state of upper limb skin microvessels of healthy normotensive working-age individuals depending on body mass index and metabolic status · 2026 · Related
  17. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics · Gerald F. Watts · 2018 · 152 citations · Cited by this paper
  18. Effective strategies for developing professional written communication in medical students · 2026 · Related
  19. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography · Maya S. Safarova · 2013 · 132 citations · Cited by this paper
  20. New approaches to the prediction of combined bone and cardiovascular pathology · 2026 · Related
  21. Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study · Nicolas Perrot · 2016 · 119 citations · Cited by this paper
  22. Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association · Eugenia Gianos · 2024 · 76 citations · Cited by this paper
  23. Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis · Ioannis T. Farmakis · 2020 · 62 citations · Cited by this paper
  24. Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol‐Lowering Therapy · Dick C. Chan · 2019 · 60 citations · Cited by this paper
  25. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials · Sining Xie · 2025 · 31 citations · Cited by this paper
  26. Rationale and design of MultiSELECt: A European Multi center S tudy on the E ffect of L ipoprotein(a) E limination by lipoprotein apheresis on C ardiovascular ou t comes · Bernd Hohenstein · 2017 · 28 citations · Cited by this paper
  27. Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) · Frederick Berro Rivera · 2025 · 24 citations · Cited by this paper
  28. Lipoprotein (a) Testing in Patients With Atherosclerotic Cardiovascular Disease in 5 Large US Health Systems · Nishant P. Shah · 2024 · 23 citations · Cited by this paper
  29. Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases · Ежов Марат Владиславович · 2021 · 18 citations · Cited by this paper
  30. Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study · Marina Blanco Ruiz · 2021 · 18 citations · Cited by this paper
  31. 2024: The Year in Cardiovascular Disease - The Year of Lipoprotein(a) – Research Advances and New Findings. · Bożena Sosnowska · 2025 · 17 citations · Cited by this paper
  32. Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia · Mita Kuchimanchi · 2018 · 11 citations · Cited by this paper
  33. Prevalence of familial hypercholesterolemia and hyperlipoproteinemia(a) in patients with premature acute coronary syndrome · У.В. Чубыкина · 2022 · 7 citations · Cited by this paper
  34. Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025) · Ежов Марат Владиславович · 2025 · 7 citations · Cited by this paper
  35. Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES · Michael J. Szarek · 2024 · 6 citations · Cited by this paper
  36. Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review · Mohit Sinha · 2024 · 6 citations · Cited by this paper
  37. Lipoprotein(a) as underestimated cardiovascular risk factor in Russia. Time to introduce into clinical practice · Olga I. Afanasieva · 2024 · 5 citations · Cited by this paper
  38. Lipoprotein(a) concentrations and secondary outcomes following first-time acute coronary syndrome: The Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS) · Malcolm E. Legget · 2025 · 4 citations · Cited by this paper
  39. Is it possible to regress atherosclerotic lesions with long-term treatment with lipoprotein apheresis? · Ulrich Julius · 2024 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)